We identified the major points that are described in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E17 guideline but have not been considered in the past multiregional clinical trials (MRCTs) used for drug approval in Japan to elucidate potential challenges in the implementation of the ICH E17 guideline in Japan. Based on the analysis of 167 MRCTs of 130 drugs, several points, such as the same dose setting and consistency between the overall and Japanese populations, in addition to good clinical practice compliance, have been well considered in ≥ 75% of MRCTs. In contrast, the use of relevant guidelines for disease and primary end point definitions, standardization of efficacy/safety information, sample size allocation, as well as training/validation on subject selection and primary end point, have been addressed less adequately and may need to be considered when planning future MRCTs. This study provides useful information for the implementation of the ICH E17 guideline in Japan.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246727 | PMC |
http://dx.doi.org/10.1002/cpt.2121 | DOI Listing |
Ther Innov Regul Sci
January 2025
Department of Biostatistics, School of Public Health, Peking University, Beijing, China.
The National Medical Products Administration of China has been implementing ICH E17, which describes the general principles for planning and designing of multi-regional clinical trials (MRCTs), yet there are several ambiguities in the execution and conduct remains in China or East Asia. In specific, pooling strategy, effect modifiers (EMs), statistical analysis, sample size allocation and their impact in alignment with global trial remains a challenge. In this paper, we explore on the criteria mentioned above under the context of China.
View Article and Find Full Text PDFTher Innov Regul Sci
January 2025
Department of Biostatistics, Peking University, Beijing, China.
In the International Council for Harmonisation (ICH) guidance on General Principles for Planning and Design of Multi-Regional Clinical Trials (E17), it is important to evaluate the consistency of treatment effect across regions in a multi-regional clinical trial (MRCT). In this paper, we elaborated on some basic considerations to evaluate consistency. We first list the design considerations, and then provide consistency evaluation and interpretation on pharmacokinetics, pharmacodynamics, efficacy, safety, and benefit-risk.
View Article and Find Full Text PDFJ Pharmacokinet Pharmacodyn
January 2025
Clinical Pharmacology Development Area, MSD K.K., Tokyo, Japan.
Model-informed drug development (MIDD) is an approach to improve the efficiency of drug development. To promote awareness and application of MIDD in Japan, the Data Science Expert Committee of the Drug Evaluation Committee in the Japan Pharmaceutical Manufacturers Association established a task force, which surveyed MIDD applications for approved products in Japan. This study aimed to reveal the trends and challenges in the use of MIDD by analyzing the survey results.
View Article and Find Full Text PDFClin Transl Sci
October 2024
EMD Serono Research and Development Institute Inc., Billerica, Massachusetts, USA.
With the International Conference on Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E17 guidelines in effect from 2018, the design of Asia-inclusive multiregional clinical trials (MRCTs) has been streamlined, thereby enabling efficient simultaneous global development. Furthermore, with the recent regulatory reforms in China and its drug administration joining the ICH as a full regulatory member, early participation of China in the global clinical development of novel investigational drugs is now feasible. This would also allow for inclusion of the region in the geographic footprint of pivotal MRCTs leveraging principles of the ICH E5 and E17.
View Article and Find Full Text PDFTher Innov Regul Sci
November 2024
Pharmaceuticals Statistics and Data Insights, Bayer Healthcare Co. Ltd. Research & Development, 6F Parkview Green Blk B, No.9 Dongdaqiao Road, Beijing, China.
In multi-regional clinical trials, planning the sample size for participating regions is essential for the evaluation of the treatment effect consistency across regions. Based on the MRCT design and sample size allocation to regions, consistency probability is usually used to predict the consistent trend between regions and the overall population, while preserving a certain proportion of the overall treatment effect. Specific enrollment characteristics in a region of interest should also be considered during the time of the sample size planning.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!